We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.49B
AUM Growth
-$101M
Cap. Flow
+$10.3M
Cap. Flow %
0.69%
Top 10 Hldgs %
30.22%
Holding
143
New
5
Increased
56
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$24.2M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$11.2M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.9M
5
MRK icon
Merck
MRK
+$9.97M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.8M
2
HCA icon
HCA Healthcare
HCA
+$32.5M
3
MCK icon
McKesson
MCK
+$13.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.83M
5
GI
EndoChoice Holdings, Inc.
GI
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.35%
2 Financials 4.56%
3 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$82.5M 5.52%
613,500
-13,000
-2% -$1.64M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$56.9M 3.81%
465,000
+197,750
+74% +$24.2M
AET
3
DELISTED
Aetna Inc
AET
$54.7M 3.66%
441,000
+900
+0.2% +$108K
MRK icon
4
Merck
MRK
$322B
$44.2M 2.95%
786,000
+170,300
+28% +$9.97M
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$39.8M 2.66%
356,000
+31,000
+10% +$3.73M
ACHC icon
6
Acadia Healthcare
ACHC
$2.76B
$38.3M 2.56%
1,157,500
+232,822
+25% +$9.03M
AGN
7
DELISTED
Allergan plc
AGN
$34.9M 2.33%
166,000
-20,000
-11% -$4.14M
RDUS
8
DELISTED
Radius Health, Inc.
RDUS
$34.6M 2.32%
910,250
+18,250
+2% +$868K
CI icon
9
Cigna
CI
$73.7B
$33.6M 2.25%
252,000
+23,500
+10% +$3.07M
WCG
10
DELISTED
Wellcare Health Plans, Inc.
WCG
$32.1M 2.15%
234,500
– –
ONCE
11
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$31.2M 2.09%
625,000
– –
ISRG icon
12
Intuitive Surgical
ISRG
$127B
$30.4M 2.04%
432,000
+27,000
+7% +$1.99M
ACRS icon
13
Aclaris Therapeutics
ACRS
$726M
$29.9M 2%
1,100,000
+84,000
+8% +$2.14M
ARDX icon
14
Ardelyx
ARDX
$1.22B
$28.4M 1.9%
2,000,000
+25,000
+1% +$355K
CELG
15
DELISTED
Celgene Corp
CELG
$28.1M 1.88%
242,500
-12,000
-5% -$1.34M
UNH icon
16
UnitedHealth
UNH
$376B
$26.4M 1.77%
+165,000
New +$24.6M
BMY icon
17
Bristol-Myers Squibb
BMY
$133B
$26.3M 1.76%
450,000
+200,000
+80% +$10.9M
COLL icon
18
Collegium Pharmaceutical
COLL
$1.15B
$24.9M 1.67%
1,600,000
+55,000
+4% +$914K
AAAP
19
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$24.9M 1.67%
930,000
– –
LLY icon
20
Eli Lilly
LLY
$1.02T
$23.9M 1.6%
325,000
+49,000
+18% +$3.65M
MDCO
21
DELISTED
Medicines Co
MDCO
$23.7M 1.59%
699,500
+18,500
+3% +$656K
SHPG
22
DELISTED
Shire pic
SHPG
$23.4M 1.56%
137,200
+4,700
+4% +$833K
PCRX icon
23
Pacira BioSciences
PCRX
$1.04B
$23M 1.54%
713,000
+209,000
+41% +$6.97M
GILD icon
24
Gilead Sciences
GILD
$162B
$19.8M 1.32%
276,500
-67,500
-20% -$5.02M
TBPH icon
25
Theravance Biopharma
TBPH
$874M
$19.1M 1.28%
600,000
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rock Springs Capital Management held 143 positions worth $1.49B, down 6.3% from $1.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2016 filing shows 5 new, 56 increased, 18 reduced and 10 closed positions. Its largest new stake was UnitedHealth: 165,000 shares worth $26.4M. The largest sale was Pfizer, an estimated $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2016 buy was UnitedHealth: 165,000 shares worth $26.4M.
  • Rock Springs Capital Management added most to Alexion Pharmaceuticals in Q4 2016, an estimated $24.2M increase.
  • Rock Springs Capital Management's biggest Q4 2016 reduction was Gilead Sciences, cutting an estimated $5.02M.
  • Rock Springs Capital Management fully exited Pfizer in Q4 2016, selling an estimated $35.8M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $1.49B portfolio in Q4 2016.
  • Rock Springs Capital Management opened 5 new positions and closed 10 in Q4 2016.
  • Rock Springs Capital Management's portfolio value fell 6.3% quarter-over-quarter to $1.49B.

Based on Rock Springs Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.